For citations:
Zhukova L.G., Artamonova E.V., Vladimirova L.Yu., Vinogradova T.V., Voronkova L.M., Zhikhorev R.S., Leushina N.V., Mironov O.V., Reznikov V.А., Semenov E.V. Clinical and demographic characteristics of patients with hormone-sensitive HER2-negative advanced breast cancer receiving ribociclib in combination with endocrine therapy or combination chemotherapy in routine clinical practice in the Russian Federation: interim results of the ValerEE study. Tumors of female reproductive system. 2025;21(3):33-49. (In Russ.) https://doi.org/10.17650/1994-4098-2025-21-3-33-49
Email this article 